Adverse effects of androgen deprivation and the limits of national tumor registries

European Urology

Volumn 61, Issue 4, 2012, Pages 701-703

  Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DENOSUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE MASS; CANCER REGISTRY; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; COGNITION; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FRACTURE; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; MONOTHERAPY; NOTE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 84857652137     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.11.034     Document Type: Editorial

References (27)

1. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
2. A. Konski, E. Sherman, and M. Krahn Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10) Int J Radiat Oncol Biol Phys 63 2005 788 794 (Pubitemid 41400067)
3. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
4. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
5. A. Nanda, M.-H. Chen, M.H. Braccioforte, B.J. Moran, and A.V. D'Amico Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
6. P. Warde, M. Mason, and K. Ding Combined androgen deprivation and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
7. M.R. Cooperberg, A.J. Vickers, J.M. Broering, and P.R. Carroll Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer 116 2010 5226 5234
8. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
9. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106 2131 (Pubitemid 46726449)
10. S.K. Bechis, P.R. Carroll, and M.R. Cooperberg Impact of age at diagnosis on prostate cancer treatment and survival J Clin Oncol 29 2011 235 241
11. M.R. Cooperberg, G. Grossfeld, D. Lubeck, and P.R. Carroll National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989 (Pubitemid 36896715)
12. V.B. Shahinian, Y.-F. Kuo, J.L. Freeman, and J.S. Goodwin Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist J Natl Cancer Inst 98 2006 839 845 (Pubitemid 43932049)
13. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
14. Prostate cancer: Asia consensus statement v.1.2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/international/ international-adaptations.asp.
15. H. Akaza Current status and prospects of androgen depletion therapy for prostate cancer Best Pract Res Clin Endocrinol Metab 22 2008 293 302 (Pubitemid 351611956)
16. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882 (Pubitemid 38807610)
17. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
18. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
19. S. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452 3458
20. C.S. Saigal, J.L. Gore, and T.L. Krupski Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500 (Pubitemid 47463063)
21. N. Keating, A. O'Malley, S. Freedland, and M. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
22. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 54 2008 816 824
23. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
24. M. Van Hemelrijck, H. Garmo, L. Holmberg, P. Stattin, and J. Adolfsson Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden Eur Urol 61 2012 690 700
25. F. Saad, Y.-M. Chen, D.M. Gleason, and J. Chin Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases Clin Genitourin Cancer 5 2007 390 396 (Pubitemid 47591666)
26. S. Punnen, M.R. Cooperberg, N. Sadetsky, and P.R. Carroll Androgen deprivation therapy and cardiovascular risk J Clin Oncol 29 2011 3510 3516
27. S.P. Porten, M.R. Cooperberg, B.R. Konety, and P.R. Carroll The example of CaPSURE: lessons learned from a national disease registry World J Urol 29 2011 265 271